Health Care · Biological Products, (No Diagnostic Substances) · Nasdaq · CIK 914475 · FYE Dec 31 · Prices AT CLOSE 2026-07-30 (USD) — end-of-day, never a live or intraday quote
Last $185.50Day +2.61%Mkt cap $18.2BP/E (FY) 38.7×1Y +35.6%Off 52W high −0.3%Vol (1Y) 32.3%
Daily closing price, split-adjusted to the current basis; 3y shown of 5,295 bars on file. Sampled to 240 points — every point is a real close, none averaged. Price return, not total return (dividends excluded). Source marketstack.
| Short interest5.3% of sh out |
| Days to cover4.9d |
| 13F net flow (QoQ)+3.03% |
| Top-10 13F concentration50.7% |
| Next report (est.)2026-08-03 |
Short interest is FINRA semi-monthly, settlement 2026-07-15. 13F figures are quarterly filings, period 2026-Q1 — a lower bound on true ownership.
| P/E (FY)38.7× |
| Sales (TTM)$3.10B |
| Earnings (TTM)$668.6M |
| ROE16.4% |
| Net margin16.7% |
| ROIC17.2% |
| EPS growth 3Y44.1% |
| Sales growth 3Y24.3% |
Screener basis: ratios from the latest reported fiscal year; Sales/Earnings are trailing twelve months in the reporting currency (USD). The P/E is a trailing FULL-YEAR P/E, not TTM. Missing lines are absent from the filings, never imputed.
| YTD+30.8% |
| 1Y+35.6% |
| 3Y+82.1% |
| 5Y+99.0% |
| 10Y+260.1% |
| Since incept. (ann.)+6.9% |
Total return through 2026-07-30 · series begins 2005-07-08. Only the windows this history actually covers are shown.
| Ann. volatility (1Y)32.3% |
| Ann. volatility (3Y)33.7% |
| Sharpe (1Y)1.18 |
| Sharpe (3Y)0.77 |
| Max drawdown (1Y)−20.9% |
| Max drawdown (3Y)−42.9% |
| Beta (3Y vs SPY)0.51 |
Daily simple returns, annualized; drawdown is peak-to-trough within the window. Beta is the OLS slope of monthly returns on SPY's over three years. Each figure is labeled by the window it was measured over — they are not comparable across windows.
| Manager | Shares | Value | % sh out | QoQ |
|---|---|---|---|---|
| BlackRock, Inc. | 13.4M | $1.8B | 13.34% | +4.3% |
| Dodge & Cox | 5.5M | $719M | 5.44% | −0.9% |
| JPMORGAN CHASE & CO | 5.4M | $701M | 5.42% | +4.6% |
| AQR CAPITAL MANAGEMENT LLC | 4.9M | $651M | 4.92% | +51.0% |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 4.7M | $623M | 4.71% | new |
| VANGUARD CAPITAL MANAGEMENT LLC | 4.5M | $594M | 4.50% | new |
| STATE STREET CORP | 4.4M | $574M | 4.34% | +2.6% |
| TWO SIGMA INVESTMENTS, LP | 3.1M | $403M | 3.05% | +210.8% |
Reported 13F long positions as filed for 2026-Q1 (change vs 2025-Q4). 13F covers US-listed long equity only — the sum is a LOWER BOUND on institutional ownership, never a total.
| Period end | Reported | EPS | EPS YoY | Revenue | Rev YoY |
|---|---|---|---|---|---|
| 2026-03-31 | 2026-05-05 | $1.91 | +2287.5% | $814.5M | +42.2% |
| 2025-12-31 | 2026-02-11 | — | — | $805.5M | +28.3% |
| 2025-09-30 | 2025-10-28 | $2.04 | +64.5% | $794.9M | +27.8% |
| 2025-06-30 | 2025-07-30 | $1.06 | +68.3% | $687.5M | +16.5% |
EPS and revenue as reported in this filer's own XBRL — our extraction of the filings, not a vendor consensus feed, and never a beat/miss claim (we carry no estimates). YoY compares the same fiscal quarter a year earlier. Next report 2026-08-03 is ESTIMATED from filing cadence (median gap 90d) — not company-confirmed.
Reportable 100%
business segments · each slice's share of TAGGED segment revenue in the latest annual filing (XBRL, as filed). Untagged revenue is excluded from the denominator, so slices need not sum to consolidated sales.
